Skip Navigation


Briefings in Functional Genomics and Proteomics Advance Access originally published online on December 24, 2008
Briefings in Functional Genomics and Proteomics 2009 8(2):126-135; doi:10.1093/bfgp/eln050
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
8/2/126    most recent
eln050v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ye, X.
Right arrow Articles by Veenstra, T. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ye, X.
Right arrow Articles by Veenstra, T. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. For permissions, please email: journals.permissions@oxfordjournals.org

This article appears in the following Briefings in Functional Genomics and Proteomics issue: Special Issue: Target Quantitative Proteomics: The Next Logical Step in Proteomics [View the issue table of contents]

Special Issue Papers

Targeted proteomics for validation of biomarkers in clinical samples

Xiaoying Ye, Josip Blonder and Timothy D. Veenstra

Corresponding author. Timothy D. Veenstra, SAIC-Frederick, Inc., National Cancer Institute at Frederick, P.O. Box B, Frederick, MD 21702, USA, Tel: +1-301-846-7186; Fax: +1-301-846-6037; E-mail: veenstra{at}ncifcrf.gov

The rapid rise and application of proteomic technologies has resulted in an exponential increase in the number of proteins that have been discovered and presented as ‘potential’ biomarkers for specific diseases. Unfortunately, the number of biomarkers approved for use by the Food and Drug Administration has not risen in likewise manner. While there are a number of reasons for this discrepancy, this glut of ‘potential’ biomarkers also indicates the need for validation methods to confirm or refute their utility in clinical diagnostics. For this reason, the emphasis on developing methods to target and measure the absolute quantity of specific proteins and peptides in complex proteomic samples has grown.

Keywords: mass spectrometry, biomarker validation, targeted proteomics, multiple-reaction monitoring, AQUA, SISCAPA


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.